Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET/MR, PET/CT and Whole Body MR in Newly Diagnosed AML
NCT02390635Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2020
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of extramedullary myeloid leukemia. Started Jul 2020; status: recruiting.
Beyond the preview
Go deeper on NCT02390635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02390635.